Coeptis Therapeutics (NASDAQ:ZSQR) Downgraded to “Sell” Rating by Wall Street Zen

Coeptis Therapeutics (NASDAQ:ZSQR) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

Coeptis Therapeutics Stock Performance

NASDAQ:ZSQR opened at $10.93 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.25 and a current ratio of 3.25. The stock has a market capitalization of $562.13 million, a P/E ratio of -4.34 and a beta of -0.22. The company has a 50 day moving average price of $11.89 and a 200 day moving average price of $12.97. Coeptis Therapeutics has a fifty-two week low of $6.80 and a fifty-two week high of $21.41.

Coeptis Therapeutics (NASDAQ:ZSQR) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.65) earnings per share for the quarter. The company had revenue of $0.11 million for the quarter. Coeptis Therapeutics had a negative return on equity of 92.29% and a negative net margin of 810.04%.

Hedge Funds Weigh In On Coeptis Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Marshall Wace LLP purchased a new position in shares of Coeptis Therapeutics during the 4th quarter worth approximately $259,000. State Street Corp boosted its position in Coeptis Therapeutics by 35.0% in the 4th quarter. State Street Corp now owns 26,830 shares of the company’s stock valued at $382,000 after buying an additional 6,962 shares during the period. Steward Partners Investment Advisory LLC boosted its position in Coeptis Therapeutics by 100.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock valued at $71,000 after buying an additional 2,500 shares during the period. Geode Capital Management LLC boosted its position in Coeptis Therapeutics by 12.6% in the 4th quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock valued at $600,000 after buying an additional 4,721 shares during the period. Finally, Yorkville Advisors Global LP purchased a new position in Coeptis Therapeutics in the 3rd quarter valued at approximately $140,000. Hedge funds and other institutional investors own 13.88% of the company’s stock.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.